DK0973928T3 - DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle - Google Patents

DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle

Info

Publication number
DK0973928T3
DK0973928T3 DK98910289.2T DK98910289T DK0973928T3 DK 0973928 T3 DK0973928 T3 DK 0973928T3 DK 98910289 T DK98910289 T DK 98910289T DK 0973928 T3 DK0973928 T3 DK 0973928T3
Authority
DK
Denmark
Prior art keywords
dna
nucleic acid
cell
introducing nucleic
transposon system
Prior art date
Application number
DK98910289.2T
Other languages
English (en)
Inventor
Zoltan Ivics
Zsuzsanna Izsvak
Perry B Hackett
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of DK0973928T3 publication Critical patent/DK0973928T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK98910289.2T 1997-03-11 1998-03-11 DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle DK0973928T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4066497P 1997-03-11 1997-03-11
US5386897P 1997-07-28 1997-07-28
US6530397P 1997-11-13 1997-11-13
PCT/US1998/004687 WO1998040510A1 (en) 1997-03-11 1998-03-11 Dna-based transposon system for the introduction of nucleic acid into dna of a cell

Publications (1)

Publication Number Publication Date
DK0973928T3 true DK0973928T3 (da) 2010-08-09

Family

ID=27365765

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98910289.2T DK0973928T3 (da) 1997-03-11 1998-03-11 DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle

Country Status (10)

Country Link
US (2) US6489458B2 (da)
EP (1) EP0973928B1 (da)
JP (2) JP2002511741A (da)
KR (1) KR20000076157A (da)
AT (1) ATE466948T1 (da)
AU (1) AU745049B2 (da)
CA (1) CA2280997C (da)
DE (1) DE69841648D1 (da)
DK (1) DK0973928T3 (da)
WO (1) WO1998040510A1 (da)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU745049B2 (en) 1997-03-11 2002-03-07 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
CA2309000A1 (en) * 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Tc1-based transposon vectors
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
CA2364267A1 (en) * 1999-02-19 2000-08-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6299850B1 (en) 1999-03-16 2001-10-09 The United States Of America As Represented By The Department Of Energy Carbon activation process for increased surface accessibility in electrochemical capacitors
US6562624B2 (en) 1999-03-17 2003-05-13 Paradigm Genetics, Inc. Methods and materials for the rapid and high volume production of a gene knock-out library in an organism
AU4711000A (en) * 1999-05-11 2000-11-21 Estuardo Aguilar-Cordova Vector-mediated delivery of integrating transposon sequences
US7196244B1 (en) * 1999-06-01 2007-03-27 University Of Utah Method of transposon-mediated mutagenesis in the nematode caenorhabditis elegans
AU1292301A (en) * 1999-10-19 2001-04-30 Minos Biosystems Limited Method for genetic manipulation
WO2001030835A1 (fr) * 1999-10-26 2001-05-03 Shanghai Bio Road Gene Development Ltd. Nouveau polypeptide, pogo transposase humaine 14, et polynucleotide codant pour ce polypeptide
WO2001030965A2 (en) * 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
CN1300827A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽—人水手转座酶19和编码这种多肽的多核苷酸
JP2001231567A (ja) * 2000-02-18 2001-08-28 Inst Of Physical & Chemical Res テロメア長の調節方法
CA2400172C (en) * 2000-02-28 2010-04-20 Genesegues, Inc. Nanocapsule encapsulation system and method
ATE307213T1 (de) * 2000-04-27 2005-11-15 Max Delbrueck Centrum Sleeping beauty, ein transposonvektor mit breitem wirtsbereich für die genetische transformation bei wirbeltieren
AU2002256304A1 (en) * 2001-04-20 2002-11-05 Srilalitha Belur Compositions for delivery of compounds to cells and methods of use
EP1308516A1 (en) * 2001-10-24 2003-05-07 ADEREGEM (Association pour le Développement de la Recherche en Génétique Moléculaire Site-directed recombinase fusion proteins and corresponding polynucleotides, vectors and kits, and their uses for site-directed DNA recombination
WO2003089618A2 (en) * 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US7164056B2 (en) 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
DE10224242A1 (de) * 2002-05-29 2003-12-11 Max Delbrueck Centrum Frog Prince, ein Transposonvektor für den Gentransfer bei Wirbeltieren
US20040172667A1 (en) * 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US7527966B2 (en) * 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
EP1380289A1 (en) * 2002-07-10 2004-01-14 Denis Bron Delivery system for pharmaceutical agents
TW200411052A (en) * 2002-07-12 2004-07-01 Takara Bio Inc Method of transferring mutation into target nucleic acid
ATE536419T1 (de) * 2003-02-10 2011-12-15 Max Delbrueck Centrum Transposon basiertes targeting- system
DE602004031284D1 (de) * 2003-02-10 2011-03-17 Max Delbrueck Centrum Transposon-system zur gezielten integration
US20080008687A1 (en) * 2003-02-10 2008-01-10 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Transposon-Based Targeting System
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
WO2005003359A1 (ja) * 2003-07-08 2005-01-13 Japan Science And Technology Corporation トランスジェニック生物を作製する方法およびシステム
US7194978B2 (en) * 2003-08-22 2007-03-27 University Of Maryland Biotechnology Institute Inducing sterility in fish by disrupting the development of the GnRH system
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
WO2005100585A2 (en) 2004-03-30 2005-10-27 Epicentre Methods for obtaining directionally truncated polypeptides
US20060294606A1 (en) * 2004-05-18 2006-12-28 Istefo Moisyadi Tn5 transposase-mediated transgenesis
US20060026699A1 (en) * 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
US20060130157A1 (en) 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
WO2009003671A2 (en) 2007-07-04 2009-01-08 Max-Delbrück-Centrum für Molekulare Medizin Hyperactive variants of the transposase protein of the transposon system sleeping beauty
DE102007048134A1 (de) * 2007-10-05 2009-04-09 Evocatal Gmbh Verfahren und Gen-Kassetten zur Klonierung, Integration und Expression mehrerer Gene eines Genclusters
CA2621155A1 (en) * 2008-02-29 2009-08-29 James Ellis Stem cell expression cassettes
US20100105140A1 (en) * 2008-07-16 2010-04-29 Fahrenkrug Scott C Plaice dna transposon system
WO2010036979A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of interferon
US9150880B2 (en) * 2008-09-25 2015-10-06 Proteovec Holding, L.L.C. Vectors for production of antibodies
WO2010036978A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of growth hormone
ES2548377T3 (es) 2008-10-27 2015-10-16 Revivicor, Inc. Ungulados inmunodeprimidos
US20120021039A1 (en) 2009-01-23 2012-01-26 Nsgene A/S Expression of neuropeptides in mammalian cells
JP5897335B2 (ja) 2009-01-23 2016-03-30 エヌエスジーン・アクティーゼルスカブＮｓＧｅｎｅ Ａ／Ｓ 改良された細胞株及びカプセル化細胞生体送達におけるその使用
WO2010118360A1 (en) * 2009-04-09 2010-10-14 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Production of proteins using transposon-based vectors
US8722964B2 (en) * 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
US9314005B2 (en) 2009-07-01 2016-04-19 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (SCID)
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
WO2011011678A2 (en) 2009-07-24 2011-01-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cytokine-cytokine signaling pathways
WO2011014721A2 (en) 2009-07-30 2011-02-03 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for pharmacokinetics
EP2462230B1 (en) * 2009-08-03 2015-07-15 Recombinetics, Inc. Methods and compositions for targeted gene modification
US20110035816A1 (en) * 2009-08-05 2011-02-10 Ostertag Eric M Genetically Modified Rat Models for Drug Metabolism
US20120151609A1 (en) 2009-08-20 2012-06-14 Ostertag Eric M Genetically Modified Rat Models for Pain
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011153440A2 (en) 2010-06-04 2011-12-08 Regents Of The University Of Minnesota Transposon mutagenesis system and methods of use
RU2447150C1 (ru) * 2010-11-26 2012-04-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Средство для генной терапии злокачественных опухолей
WO2012129198A1 (en) 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
SI2692865T1 (sl) 2012-07-30 2015-03-31 Nbe-Therapeutics Llc Technology Parc Basel S transpozicijo posredovana identifikacija specifičnih vezavnih ali funkcionalnih proteinov
CN105408473B9 (zh) 2013-05-14 2021-09-17 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
EP3105335B1 (en) 2014-02-14 2019-10-02 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
WO2015164594A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
KR20170054429A (ko) 2014-09-03 2017-05-17 제네세규스 인코포레이티드 치료용 나노입자 및 관련 조성물, 방법, 및 시스템
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
EP3851523A1 (en) 2015-03-11 2021-07-21 Board Of Regents, The University Of Texas System Transposase polypeptides and uses thereof
EP3297660A2 (en) 2015-05-20 2018-03-28 The Broad Institute Inc. Shared neoantigens
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
GB201602473D0 (en) 2016-02-11 2016-03-30 Horizon Discovery Ltd Replicative transposon system
EP3219803A1 (en) 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Enhanced sleeping beauty transposons, kits and methods of transposition
WO2020047527A2 (en) 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
CA3026778A1 (en) 2016-06-07 2017-12-14 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
KR102652827B1 (ko) 2016-06-08 2024-04-01 프레시전 인코포레이티드 Cd33 특이적 키메라 항원 수용체
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
AU2018207281B2 (en) 2017-01-10 2024-08-01 Precigen, Inc. Modulating expression of polypeptides via new gene switch expression systems
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3053133A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
SG11201907814SA (en) 2017-03-03 2019-09-27 F1 Oncology Inc Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018195019A1 (en) 2017-04-18 2018-10-25 The Broad Institute Inc. Compositions for detecting secretion and methods of use
AU2018281316B2 (en) 2017-06-07 2024-05-30 Precigen, Inc. Expression of novel cell tags
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
WO2019027850A1 (en) 2017-07-29 2019-02-07 Juno Therapeutics, Inc. CELL EXPANSION REAGENTS EXPRESSING RECOMBINANT RECEPTORS
CN111094349A (zh) 2017-08-23 2020-05-01 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 嵌合抗原受体和结合cxcr5的car-t细胞
EP3684397A4 (en) 2017-09-21 2021-08-18 The Broad Institute, Inc. SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED EDITION OF NUCLEIC ACIDS
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
CN111542596A (zh) 2017-11-01 2020-08-14 朱诺治疗学股份有限公司 产生工程化细胞的治疗性组合物的方法
MX2020004239A (es) 2017-11-01 2020-09-09 Juno Therapeutics Inc Proceso para producir una composicion de celulas t.
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
JP2021505168A (ja) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド 操作されたｔ細胞の組成物を製造するための方法
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
KR20200128703A (ko) 2018-03-06 2020-11-16 프레시전 인코포레이티드 B형 간염 백신 및 이의 용도
US12054529B2 (en) 2018-04-20 2024-08-06 Medizinische Hochschule Hannover Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
SG11202010319RA (en) 2018-04-27 2020-11-27 Iovance Biotherapeutics Inc Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
JP2022512899A (ja) 2018-11-05 2022-02-07 アイオバンス バイオセラピューティクス，インコーポレイテッド 抗ｐｄ－１抗体に対して不応性のｎｓｃｌｃ患者の治療
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
TW202039829A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 改善之腫瘤反應性ｔ細胞的選擇
MX2021005216A (es) 2018-11-05 2021-06-18 Iovance Biotherapeutics Inc Procesos para la produccion de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
EP3898949A1 (en) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
BR112021012278A2 (pt) 2018-12-21 2021-12-14 Biontech Us Inc Método e sistema para a preparação de células hla de classe ii-específica de epitopes e de síntese de cd4 + t
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220133795A1 (en) 2019-03-01 2022-05-05 Iovance Biotherapeutics, Inc. Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
CA3130872A1 (en) 2019-03-25 2020-10-01 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Enhancement of cytolytic t-cell activity by inhibiting ebag9
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
CA3141509A1 (en) 2019-06-05 2020-12-10 Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne) Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease
MX2021015433A (es) 2019-07-02 2022-06-08 Hutchinson Fred Cancer Res Vectores ad35 recombinantes y mejoras de la terapia génica relacionadas.
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CA3155727A1 (en) 2019-10-25 2021-04-29 Cecile Chartier-Courtaud Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
KR20220131892A (ko) 2019-11-05 2022-09-29 주노 쎄러퓨티크스 인코퍼레이티드 치료용 ｔ 세포 조성물의 속성 결정 방법
WO2021118990A1 (en) 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
CN113584083A (zh) 2020-04-30 2021-11-02 深圳市深研生物科技有限公司 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
EP4146793A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN115803824A (zh) 2020-05-13 2023-03-14 朱诺治疗学股份有限公司 鉴定与临床反应相关的特征的方法及其用途
IL299276A (en) 2020-06-22 2023-02-01 Univ Ramot Protein modules with cell subunits that express them and their uses
EP4199959A1 (en) 2020-08-24 2023-06-28 Charité - Universitätsmedizin Berlin A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing cd44v6
EP4199958A1 (en) 2020-08-24 2023-06-28 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (car)-expressing cells recognizing cea
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4259164A1 (en) 2020-12-11 2023-10-18 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
JP2024500403A (ja) 2020-12-17 2024-01-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球によるがんの治療
US20240041927A1 (en) 2020-12-22 2024-02-08 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
EP4019538A1 (en) 2020-12-22 2022-06-29 Charité - Universitätsmedizin Berlin Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes
CA3203531A1 (en) 2020-12-30 2022-07-07 Simon Olivares Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors containing polycistronic cassettes and methods for using them
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
WO2022198141A1 (en) 2021-03-19 2022-09-22 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
EP4326287A2 (en) 2021-04-19 2024-02-28 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
WO2023004074A2 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
TW202327631A (zh) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者
JP2024535002A (ja) 2021-09-09 2024-09-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１ ｔａｌｅｎノックダウンを使用したｔｉｌ製品を生成するためのプロセス
AR127482A1 (es) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
GB202117314D0 (en) 2021-11-30 2022-01-12 Clarke David John Cyclic nucleic acid fragmentation
WO2023122716A1 (en) 2021-12-22 2023-06-29 Vanderbilt University Next generation transpososomes
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2023150393A2 (en) 2022-02-07 2023-08-10 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
WO2023168305A1 (en) 2022-03-01 2023-09-07 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
WO2023173137A1 (en) 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
WO2023183344A1 (en) 2022-03-21 2023-09-28 Alaunos Therapeutics, Inc. Methods for identifying neoantigen-reactive t cell receptors
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230272A1 (en) 2022-05-27 2023-11-30 Kite Pharma, Inc. Non-viral delivery of cell therapy constructs
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CN116949092A (zh) * 2022-09-21 2023-10-27 上海吉量医药工程有限公司 一种转座子系统及其应用
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
EP4353253A1 (en) 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Purification of tcr-modified t cells using tcr-specific car-nk cells
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
WO2024197072A2 (en) 2023-03-21 2024-09-26 Alaunos Therapeutics, Inc. Identification of neoantigen-reactive t cell receptors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631259A (en) 1983-05-04 1986-12-23 Board Of Regents Of The University Of Michigan Transposon in cloning DNA
WO1988001646A1 (en) 1986-08-26 1988-03-10 Allelix Inc. Universal system for transposon mutagenesis
FR2627508B1 (fr) 1988-02-22 1990-10-05 Eurolysine Procede pour l'integration d'un gene choisi sur le chromosome d'une bacterie et bacterie obtenue par ledit procede
EP0485701A1 (en) 1990-09-28 1992-05-20 American Cyanamid Company Insertion of DNA by modified transposons
ATE169061T1 (de) 1990-10-25 1998-08-15 Clague Pitman Hodgson Methode des gentransfers mittels retrotransposons
CA2116107A1 (en) 1991-09-05 1993-03-18 George Y. Wu Targeted delivery of poly-or oligonucleotides to cells
CA2135295A1 (en) 1992-06-17 1993-12-23 Chu Jung Arabinogalactan derivatives and uses thereof
US6225121B1 (en) 1992-09-14 2001-05-01 Institute Of Molecular Biology And Biotechnology/Forth Eukaryotic transposable element
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
AU7321294A (en) 1993-06-30 1995-01-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Transformed eukaryotic cells, and transposon-based transformation vectors
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
CA2180202A1 (en) 1995-06-30 1996-12-31 Mika Moriya Method of amplifying gene using artificial transposon
WO1997015679A1 (en) 1995-10-27 1997-05-01 The Trustees Of The University Of Pennsylvania Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
JP2001503962A (ja) 1996-02-09 2001-03-27 ヘット ネーデルランツ カンケル インスティチュート 細胞のゲノム中に組込まれる付加核酸物質を細胞に付与するためのベクターおよび方法
US5948681A (en) 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
US5928888A (en) 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
WO1998024479A1 (en) 1996-12-02 1998-06-11 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
AU745049B2 (en) * 1997-03-11 2002-03-07 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
WO1998056903A1 (en) 1997-06-13 1998-12-17 President And Fellows Of Harvard College Methods and uses for transposon-based gene targeting
CA2309000A1 (en) 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Tc1-based transposon vectors
TR200003441T2 (tr) 1998-05-20 2001-04-20 Expression Genetics, Inc. Hepatositi hedefleyen polietilen gliko-ekli poli-l-lisin polimerik bir gen taşıyıcı
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
AU4711000A (en) 1999-05-11 2000-11-21 Estuardo Aguilar-Cordova Vector-mediated delivery of integrating transposon sequences
WO2001030965A2 (en) 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
ATE307213T1 (de) 2000-04-27 2005-11-15 Max Delbrueck Centrum Sleeping beauty, ein transposonvektor mit breitem wirtsbereich für die genetische transformation bei wirbeltieren
US20020115216A1 (en) 2000-05-19 2002-08-22 Steer Clifford J. Composition for delivery of compounds to cells
US20060057553A1 (en) 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
JP2004267001A (ja) 2000-08-16 2004-09-30 Kansai Tlo Kk トランスジェニック哺乳動物及びその作製方法並びにこれを用いた遺伝子機能の解明方法
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same

Also Published As

Publication number Publication date
AU6456998A (en) 1998-09-29
CA2280997C (en) 2013-05-28
EP0973928B1 (en) 2010-05-05
ATE466948T1 (de) 2010-05-15
DE69841648D1 (de) 2010-06-17
US6489458B2 (en) 2002-12-03
JP2008271981A (ja) 2008-11-13
CA2280997A1 (en) 1998-09-17
KR20000076157A (ko) 2000-12-26
US7148203B2 (en) 2006-12-12
AU745049B2 (en) 2002-03-07
US20020016975A1 (en) 2002-02-07
EP0973928A1 (en) 2000-01-26
JP2002511741A (ja) 2002-04-16
US20030124668A1 (en) 2003-07-03
WO1998040510A1 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
DK0973928T3 (da) DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
AU3199699A (en) Modified nucleotides and methods useful for nucleic acid sequencing
ATE319854T1 (de) Enzymaktive dna moleküle
ATE364718T1 (de) Verfahren zur vervielfältigung von nukleinsäure
ATE352638T1 (de) REVERSE ßTWO-HYBRIDß-SYSTEME
ES2195171T3 (es) Sistema de transposicion in vitro usando transposasa tn5 modificada.
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
EP1961826A3 (en) A method for direct nucleic acid sequencing
ATE317440T1 (de) Neuartige methode zur integration von fremd-dna ins eukaryotische genom
SE8801070D0 (sv) Method for immobilizing a dna sequence on a solid support
ATE525472T1 (de) Verfahren zur homologen rekombination
DE69524740D1 (de) Thymidin-kinase-mutanten
TR199802648A3 (tr) Gen tedavisi için nüklein asit yapilari.
WO1998054313A3 (en) Dna methyltransferase genomic sequences and antisense oligonucleotides
DE69823372T8 (de) Verfahren und reagentiensatz zur amplifizierung, sequenzierung und typisierung von hla i genen
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
AU9476598A (en) Method to make fluorescent nucleotide photoproducts for dna sequencing and analysis
DE69937056D1 (de) Verfahren zur transformation von tierzellen
ATE427959T1 (de) Gereinigtes sr-p70 protein
ATE211180T1 (de) Verfahren zur nicht-radioaktiven detektion von membran-gebundenen nukleinsäuren und testkit
EP0643719A4 (en) NUCLEIC ACID SEQUENCES ENCODING NUCLEIC ACID SEQUENCES ENCODING THE INTERLEUKIN-9 RECEPTOR, OR COMPLEMENTARY TO THESE SEQUENCES.
ES2189560A1 (es) Dna polimerasa k, nuevo marcador tumoral.
DE60130465D1 (de) Mutierte muskelspezifische enhancer
GB9827908D0 (en) Nucleic acid sequencing method